KIRKLAND, QC, Jan. 30 /CNW Telbec/ - Pfizer Canada announced today that
it will streamline its Canadian pharmaceutical operations to improve
performance and to better meet emerging customer and business needs. The
streamlining initiative will result in the reduction of approximately
285 positions over the next 6 months and will impact all parts of the
organization including head office and field-based employees.
The changes at Pfizer Canada are part of a company-wide initiative Pfizer
is undertaking to better align its resources with business and customer needs.
Earlier this month, Pfizer Inc announced it would be introducing fundamental
changes to reduce costs and increase efficiency across its research,
manufacturing and pharmaceutical operations. The global initiative will result
in the reduction of approximately 10,000 positions around the world over the
next two years.
"We have undertaken a comprehensive review of every aspect of our
business to determine the steps we need to take to position Pfizer for future
success," said Jean-Michel Halfon, President of Pfizer Canada Inc. "This
exercise has forced us to rethink how we do things, how we prioritize and how
we allocate resources in order to better meet the needs of an evolving
healthcare market. These decisions are difficult and we are sorry to see
valued colleagues leave our organization. However, consistent with Pfizer's
long-standing values, we will provide impacted employees with support services
during their transitions."
"Pfizer has a very robust R&D pipeline and exciting products in
development in a wide range of therapeutic areas including oncology, arthritis
and pain, cardiovascular disease and infectious diseases. We are also looking
forward to several promising product launches this year in Canada," concluded
For further information:
For further information: Sophie McCann, Director, Corporate
Communications, Pfizer Canada Inc., Media Line: 1-866-973-4937